BioCentury
ARTICLE | Distillery Therapeutics

Transplant

January 8, 2019 1:06 AM UTC

Mouse studies suggest inhibiting CORO1A or its downstream mediator PDE-4 could help treat heart transplant and skin graft rejection. In a mouse model of heart transplantation, systemic CORO1A knockout decreased vasculopathy compared with normal expression. In a mouse model of skin graft transplantation, systemic CORO1A knockout or a PDE-4 inhibitor tool compound increased skin allograft survival compared with normal CORO1A expression or vehicle, respectively. In two other mouse models of skin graft transplantation, adoptive transfer of CORO1A-knockout T cells increased skin allograft survival compared with transfer of unmodified T cells. Next steps could include identifying and testing CORO1A inhibitors in the models.

AstraZeneca plc, Allergan plc, Merck & Co. Inc. and Mitsubishi Tanabe Pharma Corp. market Daliresp roflumilast, a PDE-4 inhibitor, to treat chronic obstructive pulmonary disease (COPD)...